TCRX Graph | TSCAN THERAPEUTICS, INC.

TCRX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $1.05M; Research and development $23.40M; Operating expenses $31.54M; Net income -$30.36M.
2026-03-31: Revenue $982.00K; Research and development $21.90M; Operating expenses $30.12M; Net income -$28.67M.
2025-12-31: Revenue $2.57M*; Research and development $20.04M*; Operating expenses $26.43M*; Net income -$22.98M*.
2025-09-30: Revenue $2.51M; Research and development $31.69M; Operating expenses $39.56M; Net income -$35.71M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	$1.05M	$23.40M	$31.54M	-$30.36M
2026-03-31	$982.00K	$21.90M	$30.12M	-$28.67M
2025-12-31	$2.57M*	$20.04M*	$26.43M*	-$22.98M*
2025-09-30	$2.51M	$31.69M	$39.56M	-$35.71M
2025-06-30	$3.08M	$32.63M	$41.73M	-$36.95M
2025-03-31	$2.17M	$29.79M	$38.42M	-$34.13M
2024-09-30	$1.05M	$26.26M	$33.67M	-$29.89M
2024-06-30	$536.00K	$26.88M	$34.65M	-$31.66M
2024-03-31	$566.00K	$24.86M	$31.94M	-$30.14M
2023-09-30	$3.89M	$22.74M	$28.64M	-$23.00M
2023-06-30	$3.15M	$21.23M	$27.76M	-$24.05M
2023-03-31	$6.80M	$21.78M	$29.55M	-$22.56M
2022-09-30	$3.36M	$15.03M	$19.94M	-$16.25M
2022-06-30	$4.06M	$14.49M	$19.30M	-$15.10M
2022-03-31	$3.02M	$14.69M	$19.18M	-$16.16M
2021-09-30	$2.41M	$14.21M	$18.25M	-$15.84M
2021-06-30	$2.85M	$10.80M	$13.53M	-$10.67M
2021-03-31	$2.03M	$7.34M	$9.95M	-$7.91M
2020-09-30	$290.00K	$5.81M	$7.46M	-$7.17M
2020-06-30	(m)	$4.50M	$5.62M	-$5.61M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Net income
2026-06-30	$2.03M	$45.31M	$61.66M	-$59.02M
2025-06-30	$5.25M	$62.42M	$80.15M	-$71.08M
2024-06-30	$1.10M	$51.73M	$66.59M	-$61.80M
2023-06-30	$9.95M	$43.01M	$57.30M	-$46.61M
2022-06-30	$7.08M	$29.18M	$38.49M	-$31.25M
2021-06-30	$4.88M	$18.14M	$23.47M	-$18.59M
2020-06-30	(m)	$8.80M	$11.25M	-$11.15M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Net income
2025-09-30	$7.76M	$94.11M	$119.71M	-$106.79M
2024-09-30	$2.15M	$78.00M	$100.26M	-$91.69M
2023-09-30	$13.84M	$65.75M	$85.94M	-$69.61M
2022-09-30	$10.44M	$44.22M	$58.43M	-$47.50M
2021-09-30	$7.29M	$32.35M	$41.73M	-$34.42M
2020-09-30	$290.00K	$14.61M	$18.71M	-$18.32M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$10.32M	$114.15M	$146.14M	$0.00	-$129.77M
2024-12-31	$2.82M	$107.35M	$137.64M	(m)	-$127.50M
2023-12-31	$21.05M	$88.15M	$114.51M	(m)	-$89.22M
2022-12-31	$13.54M	$59.82M	$80.17M	(m)	-$66.22M
2021-12-31	$10.14M	$44.95M	$58.78M	(m)	-$48.63M
2020-12-31	$1.08M	$20.58M	$27.32M	(m)	-$26.13M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
CERO THERAPEUTICS HOLDINGS, INC. (CERO)	United States	$0.007B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)	United States	$0.006B
AIM ImmunoTech Inc. (AIM)	United States	$0.006B
Senti Biosciences Holdings, Inc. (SNTI)	United States	$0.011B	-0.70
IN8BIO, INC. (INAB)	United States	$0.012B	-0.76
PharmaCyte Biotech, Inc. (PMCB)	United States	$0.005B
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)	United States	$0.013B	-1.05
INTENSITY THERAPEUTICS, INC. (INTS)	United States	$0.013B	-1.08
WINDTREE THERAPEUTICS INC /DE/ (WINT)	United States	$0.003B	-0.32
VivoSim Labs, INC. (VIVS)	United States	$0.003B